Acinetobacter calcoaceticus, a soil microbe, contains molecular sequences which resemble those found in neurofilaments of the brain tissue. It was hypothesized that if cattle ingest large amounts of feedstuff containing A. calcoaceticus, they may develop an autoimmune reaction, with consequences of pathological changes associated with transmissible spongiform encephalopathies (TSEs). The hypothesis was tested using a small number of serum samples collected from cattle and it was found that affected individuals had elevated serum antibody levels to this organism. If this finding was substantiated, it would provide a possible means of diagnosing TSEs in vivo. In the present communication, a larger number of cattle, elk and sheep with or without TSEs were tested using A. calcoaceticus whole cell and lipopolysaccharide antigens as well as myelin basic protein (MBP). It was found that antibody levels in normal and affected animals overlapped considerably, thus casting doubt on the usefulness of these antigens as diagnostic tools for TSEs and on the hypothesis of A. calcoaceticus being a cause of TSEs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0165-2427(02)00209-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the potential of in alleviation of aluminium stress in .
3 Biotech
January 2025
Department of Agronomy, Abdul Wali Khan University, Mardan, 23200 Khyber Pakhtunkhwa Pakistan.
Soil contamination with toxic heavy metals [such as aluminum (Al)] is becoming a serious global problem due to the rapid development of the social economy. Although plant growth-promoting rhizo-bacteria (PGPR) are the major protectants to alleviate metal toxicity, the study of these bacteria to ameliorate the toxic effects of Al is limited. Therefore, the present study was conducted to investigate the combined effects of different levels of (5 ppm and 10 ppm) of accession number of MT123456 on plant growth and biomass, photosynthetic pigments, gas exchange attributes, oxidative stress and response of antioxidant compounds (enzymatic and nonenzymatic), and their specific gene expression, sugars, nutritional status of the plant, organic acid exudation pattern and Al accumulation from the different parts of the plants, which was spiked with different levels of Al [0 µM (i.
View Article and Find Full Text PDFTherapeutic Drug Monitoring of High-dose Sulbactam in Pediatric Patients: Preliminary Data From a Prospective Observational Pharmacokinetic Study.
Pediatr Infect Dis J
October 2024
From the Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine.
Background: Rates of carbapenem-resistant Acinetobacter baumannii are rising in Thailand. Although high-dose (HD) sulbactam is recommended for treating carbapenem-resistant A. baumannii infections, data on plasma sulbactam concentrations in children are limited.
View Article and Find Full Text PDFassessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations.
Antimicrob Agents Chemother
December 2024
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Sulbactam-durlobactam is approved for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of complex. Patients with serious infections may require support with continuous renal replacement therapy (CRRT), which presents challenges for optimal dosing of antibiotics. Sulbactam-durlobactam dosing regimens were derived for this population using an CRRT model and Monte Carlo simulation (MCS).
View Article and Find Full Text PDFUnraveling sulbactam-durlobactam: insights into its role in combating infections caused by .
Expert Rev Anti Infect Ther
January 2025
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
Introduction: Carbapenem-resistant (CRAB) is a critical priority pathogen posing a substantial threat to our public health due to its virulence and resistance to broad-spectrum antimicrobials. Sulbactam-durlobactam (Xacduro) is a newly approved β-lactam-β-lactamase inhibitor combination agent with potent and activity against CRAB. The phase III randomized trial (ATTACK) demonstrated the safety and efficacy of sulbactam-durlobactam in combination with imipenem-cilastatin as background therapy in treating adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by CRAB.
View Article and Find Full Text PDFNosocomial outbreak due to a novel sequence type of carbapenem-resistant Acinetobacter seifertii.
Am J Infect Control
November 2024
Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; Programa de Pós-Graduação em Ciências Médicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Bioinformatic Core, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; Departamento de Microbiologia, Imunologia e Parasitologia, Instituto de Ciências Básicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Background: Acinetobacter seifertii, a member of A baumannii-calcoaceticus complex, can be considered a pathogen of concern due to the presence of resistance genes. The aim of the study was to describe an outbreak of carbapenem-resistant A seifertii among neonates admitted to the neonatal intensive care unit (NICU) at a tertiary care hospital.
Methods: All patients with carbapenem-resistant A seifertii diagnosed and admitted to the NICU from June 2023 to October 2023 were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!